Medicaid Drug Utilization Review (DUR) Board Meeting Agenda for May 14, 2010

The Drug Utilization Review (DUR) Board will meet on May 14, 2010, from 9:00 a.m. to 4:30 p.m., Meeting Room 6, Concourse, Empire State Plaza, Albany, New York.

Agenda Items:

1. Board action on pending DUR topics (refer to the February 18, 2010 Meeting Summary)

2. Drug Utilization Review of the following drugs/drug classes:

  1. Quinine
  2. Qualaquin (quinine sulfate)
  1. Cyclosporine Ophthalmic Emulsion
  2. Restasis (cyclosporine)
  1. Buprenorphine
  2. Suboxone (buprenorphine/naloxone), Subutex (buprenorphine)
  1. Oxycodone Controlled Release
  2. Oxycontin (oxycodone HCl controlled-release), oxycodone HCl CR,

3. Utilization Threshold Presentation

4. Prescriber Education Program (PEP) Update

Agenda Timeline (subject to change based on meeting proceedings)

Time Agenda Topic
9:00 - 9:15 Welcome and Introductions
9:15 - 10:30 Board actions on pending DUR topics
10:30 - 11:00 Break
11:00 - 11:30 Public Comment Period*
11:30 - 12:30 Drug Utilization Review: Quinine, Cyclosporine Ophthalmic Emulsion
12:30 - 1:30 Lunch ( Executive Session)
1:30 - 2:30 Drug Utilization Review: Buprenorphine, Oxycodone Controlled Release
2:30 - 3:00 Utilization Threshold Presentation
3:00 - 3:30 Prescriber Education Program (PEP) Update
3:30 - 3:45 Final Comments/Adjournment

*Interested parties must notify the Drug Utilization Review Manager at least one (1) week prior to the meeting of their request to address the DUR Board during the public comment period. Requests may be made by calling 518-486-3209 or e-mailing (please reference DUR Board). Public comments are limited to the specific topics on the agenda, must be brief (2 minutes), and the total comment period will not exceed sixty (60) minutes. All written statements, up to two (2) pages in length must be received up to one (1) week in advance of the meeting. These statements should summarize key points.

NOTE: For those submitting information greater than two (2) pages in length for DUR Board review and consideration must do so at least two (2) weeks prior to the meeting date or the Board may not have ample time to review the information.

Posted 04/16/2010